Published in J Clin Invest on December 01, 2005
Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc (2007) 6.94
Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells (2009) 3.01
Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol (2011) 2.97
Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol (2012) 2.84
Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med (2009) 2.51
Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-κB. Nat Med (2014) 2.30
The association between higher serum ferritin level and lower bone mineral density is prominent in women ≥45 years of age (KNHANES 2008-2010). Osteoporos Int (2013) 2.07
Disorders of bone remodeling. Annu Rev Pathol (2011) 2.05
Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev (2012) 1.97
Hyponatremia-induced osteoporosis. J Bone Miner Res (2010) 1.95
Impact exercise increases BMC during growth: an 8-year longitudinal study. J Bone Miner Res (2008) 1.93
Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int (2008) 1.68
How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int (2010) 1.68
Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci (2007) 1.61
Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell (2010) 1.60
Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One (2008) 1.60
Adaptation of connexin 43-hemichannel prostaglandin release to mechanical loading. J Biol Chem (2008) 1.52
Association of coronary artery and aortic calcium with lumbar bone density: the MESA Abdominal Aortic Calcium Study. Am J Epidemiol (2008) 1.45
The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J (2007) 1.43
Vascular calcification and osteoporosis--from clinical observation towards molecular understanding. Osteoporos Int (2006) 1.42
Synaptotagmin VII regulates bone remodeling by modulating osteoclast and osteoblast secretion. Dev Cell (2008) 1.38
Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab (2009) 1.33
Akt promotes BMP2-mediated osteoblast differentiation and bone development. J Cell Sci (2009) 1.31
Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis (2007) 1.23
Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int (2007) 1.22
Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest (2006) 1.20
Erk1 positively regulates osteoclast differentiation and bone resorptive activity. PLoS One (2011) 1.19
Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol (2007) 1.19
Novel functions for NFκB: inhibition of bone formation. Nat Rev Rheumatol (2010) 1.19
Transplantation of mesenchymal stem cells from young donors delays aging in mice. Sci Rep (2011) 1.13
An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption. Br J Pharmacol (2008) 1.13
Selective signaling by Akt2 promotes bone morphogenetic protein 2-mediated osteoblast differentiation. Mol Cell Biol (2009) 1.12
Signaling networks that control the lineage commitment and differentiation of bone cells. Crit Rev Eukaryot Gene Expr (2009) 1.11
Gsα enhances commitment of mesenchymal progenitors to the osteoblast lineage but restrains osteoblast differentiation in mice. J Clin Invest (2011) 1.08
An enhancer 20 kilobases upstream of the human receptor activator of nuclear factor-kappaB ligand gene mediates dominant activation by 1,25-dihydroxyvitamin D3. Mol Endocrinol (2008) 1.08
The link between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab (2008) 1.08
Indirect regulation of PTH by estrogens may require FGF23. J Am Soc Nephrol (2009) 1.07
Influence of osteoporosis on fracture fixation--a systematic literature review. Osteoporos Int (2008) 1.06
Association of leptin, 25-hydroxyvitamin D, and parathyroid hormone in women. Nutr Cancer (2009) 1.05
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int (2013) 1.05
Estrogen receptor α36 mediates a bone-sparing effect of 17β-estrodiol in postmenopausal women. J Bone Miner Res (2011) 1.04
Postmenopausal osteoporosis: the role of immune system cells. Clin Dev Immunol (2013) 1.04
Bone mineral density and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis, Abdominal Aortic Calcium Study. Atherosclerosis (2009) 1.03
The menstrual cycle: a biological marker of general health in adolescents. Ann N Y Acad Sci (2008) 1.03
Targeting integrins to promote bone formation and repair. Nat Rev Endocrinol (2013) 1.02
Hepatic osteodystrophy and liver cirrhosis. World J Gastroenterol (2010) 1.01
Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis. Arthritis Res Ther (2009) 1.01
Essential role of nuclear factor of activated T cells (NFAT)-mediated Wnt signaling in osteoblast differentiation induced by strontium ranelate. J Biol Chem (2010) 1.00
Sympathetic control of bone mass regulated by osteopontin. Proc Natl Acad Sci U S A (2011) 0.99
Link between obstructive sleep apnea and increased bone resorption in men. Osteoporos Int (2008) 0.99
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J (2015) 0.98
Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PLoS One (2012) 0.98
Progressive ankylosis protein (ANK) in osteoblasts and osteoclasts controls bone formation and bone remodeling. J Bone Miner Res (2010) 0.98
A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis (2013) 0.97
Osteoclasts: New Insights. Bone Res (2013) 0.97
Orai1-mediated calcium entry plays a critical role in osteoclast differentiation and function by regulating activation of the transcription factor NFATc1. FASEB J (2011) 0.96
Hepatic osteodystrophy is common in patients with noncholestatic liver disease. Dig Dis Sci (2011) 0.96
Serum response factor regulates bone formation via IGF-1 and Runx2 signals. J Bone Miner Res (2012) 0.95
Pro-survival effects of 17β-estradiol on osteocytes are mediated by nitric oxide/cGMP via differential actions of cGMP-dependent protein kinases I and II. J Biol Chem (2011) 0.95
Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum (2011) 0.95
Drivers of age-related inflammation and strategies for healthspan extension. Immunol Rev (2015) 0.94
Oleuropein enhances osteoblastogenesis and inhibits adipogenesis: the effect on differentiation in stem cells derived from bone marrow. Osteoporos Int (2010) 0.94
Therapeutic application of mesenchymal stem cells in bone and joint diseases. Clin Exp Med (2012) 0.93
Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis. Expert Opin Ther Targets (2010) 0.92
Ginseng saponins and the treatment of osteoporosis: mini literature review. J Ginseng Res (2013) 0.92
Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study. Osteoporos Int (2007) 0.92
Resolvin E1 and chemokine-like receptor 1 mediate bone preservation. J Immunol (2012) 0.92
Aromatase inhibitors and bone loss. Oncology (Williston Park) (2006) 0.92
The contribution of cortical and trabecular tissues to bone strength: insights from denosumab studies. Clin Cases Miner Bone Metab (2013) 0.90
c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions. PLoS One (2012) 0.90
Effects of Nrf2 deficiency on bone microarchitecture in an experimental model of osteoporosis. Oxid Med Cell Longev (2014) 0.89
Plasma inflammatory mediators associated with bone metabolism in COPD. COPD (2010) 0.89
A review of minodronic acid hydrate for the treatment of osteoporosis. Clin Interv Aging (2013) 0.89
Eldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidol. J Bone Miner Metab (2013) 0.89
Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis. Int J Endocrinol (2014) 0.89
Effects of remifemin treatment on bone integrity and remodeling in rats with ovariectomy-induced osteoporosis. PLoS One (2013) 0.88
Concerted stimuli regulating osteo-chondral differentiation from stem cells: phenotype acquisition regulated by microRNAs. Acta Pharmacol Sin (2009) 0.88
Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice. Hum Mol Genet (2013) 0.87
Synergistic effects of green tea polyphenols and alphacalcidol on chronic inflammation-induced bone loss in female rats. Osteoporos Int (2010) 0.87
Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. Clin Interv Aging (2010) 0.87
Absence of ERRalpha in female mice confers resistance to bone loss induced by age or estrogen-deficiency. PLoS One (2009) 0.87
Tanshinone IIA blocks dexamethasone-induced apoptosis in osteoblasts through inhibiting Nox4-derived ROS production. Int J Clin Exp Pathol (2015) 0.87
Constitutively active parathyroid hormone receptor signaling in cells in osteoblastic lineage suppresses mechanical unloading-induced bone resorption. J Biol Chem (2007) 0.86
Once-yearly zoledronic acid in hip fracture prevention. Clin Interv Aging (2009) 0.86
Role of fibroblast growth factor 2 and Wnt signaling in anabolic effects of parathyroid hormone on bone formation. J Cell Physiol (2012) 0.86
The mammalian lectin galectin-8 induces RANKL expression, osteoclastogenesis, and bone mass reduction in mice. Elife (2015) 0.86
Nuclear receptors in bone physiology and diseases. Physiol Rev (2013) 0.86
Oxytocin reverses osteoporosis in a sex-dependent manner. Front Endocrinol (Lausanne) (2015) 0.85
Molecular Aspects of Bone Resorption in β-Thalassemia Major. Cell J (2015) 0.85
Association between osteoporosis and psoriasis: results from the Longitudinal Health Insurance Database in Taiwan. Osteoporos Int (2012) 0.85
Systemic transplantation of human adipose-derived stem cells stimulates bone repair by promoting osteoblast and osteoclast function. J Cell Mol Med (2011) 0.85
Deletion of Orai1 alters expression of multiple genes during osteoclast and osteoblast maturation. Cell Calcium (2012) 0.85
Transplantation of SHED prevents bone loss in the early phase of ovariectomy-induced osteoporosis. J Dent Res (2014) 0.85
A Mediterranean diet enriched with olive oil is associated with higher serum total osteocalcin levels in elderly men at high cardiovascular risk. J Clin Endocrinol Metab (2012) 0.85
Roles of leptin in bone metabolism and bone diseases. J Bone Miner Metab (2015) 0.85
Anti-osteoclastogenic activity of matairesinol via suppression of p38/ERK-NFATc1 signaling axis. BMC Complement Altern Med (2014) 0.84
A nomogram for predicting osteoporosis risk based on age, weight and quantitative ultrasound measurement. Osteoporos Int (2007) 0.84
A diarylheptanoid phytoestrogen from Curcuma comosa, 1,7-diphenyl-4,6-heptadien-3-ol, accelerates human osteoblast proliferation and differentiation. Phytomedicine (2013) 0.83
17β-Estradiol inhibits ER stress-induced apoptosis through promotion of TFII-I-dependent Grp78 induction in osteoblasts. Lab Invest (2014) 0.83
Estrogen augments shear stress-induced signaling and gene expression in osteoblast-like cells via estrogen receptor-mediated expression of beta1-integrin. J Bone Miner Res (2010) 0.83
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell (1997) 16.78
The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell (2002) 15.20
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 11.99
High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med (2002) 11.28
Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell (2000) 7.87
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 7.69
Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev (2001) 6.77
Effect of Vitamin D on falls: a meta-analysis. JAMA (2004) 6.64
A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet (2001) 6.56
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature (2005) 6.43
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet (2001) 5.72
Therapeutic approaches to bone diseases. Science (2000) 5.60
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem (2005) 5.33
Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med (2004) 4.34
Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev (2002) 3.46
Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med (2004) 3.32
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res (2004) 3.17
Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology (1970) 3.16
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest (2000) 2.94
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med (1996) 2.92
Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest (1982) 2.92
Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet (2003) 2.86
Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res (2004) 2.63
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res (2005) 2.61
Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology (1998) 2.54
Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med (Berl) (2005) 2.48
Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab (2001) 2.43
Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res (1990) 2.39
Clinical practice. Postmenopausal osteoporosis. N Engl J Med (2005) 2.38
A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest (2003) 2.37
Clinical practice. Screening for osteoporosis. N Engl J Med (2005) 2.25
Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA (2004) 2.20
Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science (2004) 2.15
Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone (2002) 2.13
High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. Mol Cell Biol (2002) 1.95
Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem (2004) 1.91
Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res (1996) 1.86
Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest (1997) 1.81
Endocrinology: bone adaptation requires oestrogen receptor-alpha. Nature (2003) 1.76
Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology (1995) 1.75
Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem (2005) 1.69
Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology (2004) 1.66
Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biol (2003) 1.64
Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol (2004) 1.63
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med (2005) 1.56
The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem (2005) 1.54
Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab (1996) 1.53
Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res (2004) 1.50
Long-term safety of bisphosphonates. J Clin Endocrinol Metab (2005) 1.50
Molecular studies of identification of genes for osteoporosis: the 2002 update. J Endocrinol (2003) 1.48
Bone biomechanical properties in LRP5 mutant mice. Bone (2004) 1.47
Meta-analysis of COL1A1 Sp1 polymorphism in relation to bone mineral density and osteoporotic fracture. Bone (2003) 1.44
Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study. J Bone Miner Res (2004) 1.44
T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res (2001) 1.43
Fluid shear stress induces beta-catenin signaling in osteoblasts. Calcif Tissue Int (2004) 1.42
Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA (2003) 1.38
Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun (2005) 1.37
Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab (2003) 1.36
A treatise on dislocations and on fractures of the joints: fractures of the neck of the thigh-bone. 1823. Clin Orthop Relat Res (2007) 1.34
Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc Natl Acad Sci U S A (2004) 1.32
Correlates of osteoprotegerin levels in women and men. Osteoporos Int (2002) 1.31
Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab (2003) 1.28
Relations between histologic indices of bone formation: implications for the pathogenesis of spinal osteoporosis. J Bone Miner Res (1995) 1.28
Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res (2005) 1.27
Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J Bone Miner Res (2002) 1.26
Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin d status, bone mass, and renal function in the frail and very old: a cohort study. J Clin Endocrinol Metab (2004) 1.25
beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res (2004) 1.25
Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study. J Clin Endocrinol Metab (2004) 1.23
Minireview: transcriptional regulation in development of bone. Endocrinology (2004) 1.21
Female estrogen receptor beta-/- mice are partially protected against age-related trabecular bone loss. J Bone Miner Res (2001) 1.20
Estrogen receptor-related receptor alpha: a mediator of estrogen response in bone. J Clin Endocrinol Metab (2005) 1.17
Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res (2003) 1.17
Dose-response of estrogen on bone versus the uterus in ovariectomized mice. Eur J Endocrinol (2004) 1.16
5-Lipoxygenase metabolites inhibit bone formation in vitro. Endocrinology (1998) 1.15
Influence of LRP5 polymorphisms on normal variation in BMD. J Bone Miner Res (2004) 1.14
Interactions of interleukin-6 promoter polymorphisms with dietary and lifestyle factors and their association with bone mass in men and women from the Framingham Osteoporosis Study. J Bone Miner Res (2004) 1.13
Central control of bone remodeling. Biochem Biophys Res Commun (2005) 1.11
Effect of osteoclast activating factor from human leukocytes on bone metabolism. J Clin Invest (1975) 1.11
LRP5 gene polymorphisms predict bone mass and incident fractures in elderly Australian women. Bone (2005) 1.11
Association of oestrogen receptor alpha gene polymorphisms with postmenopausal bone loss, bone mass, and quantitative ultrasound properties of bone. J Med Genet (2005) 1.08
Role of nitric oxide and prostaglandins in mechanically induced bone formation. J Bone Miner Res (1998) 1.05
Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial. J Bone Miner Res (2004) 1.05
Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenet Genomics (2005) 1.05
Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. Am J Med (2001) 1.04
Do dietary calcium and age explain the controversy surrounding the relationship between bone mineral density and vitamin D receptor gene polymorphisms? J Bone Miner Res (1998) 1.03
Serum parathyroid hormone predicts time to fall independent of vitamin D status in a frail elderly population. J Clin Endocrinol Metab (2004) 1.03
Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab (2004) 1.02
Genetic determinants of bone mass. Curr Opin Rheumatol (2004) 1.01
Vitamin D receptor gene polymorphisms are associated with the risk of fractures in postmenopausal women, independently of bone mineral density. J Clin Endocrinol Metab (2005) 1.01
Association of interleukin-6 promoter variant with bone mineral density in pre-menopausal women. J Hum Genet (2003) 0.98
Calcium-sensing receptor gene polymorphism A986S does not predict serum calcium level, bone mineral density, calcaneal ultrasound indices, or fracture rate in a large cohort of elderly women. Calcif Tissue Int (2003) 0.98
The relationship among serum insulin-like growth factor-I, insulin-like growth factor-I gene polymorphism, and bone mineral density in postmenopausal women in Korea. Am J Obstet Gynecol (2002) 0.95
Expression of membrane-bound and soluble receptor activator of NF-kappaB ligand (RANKL) in human T cells. Immunol Lett (2004) 0.94
Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae. J Clin Invest (1995) 0.93